Wegovy 1.0mg: the third step in the titration schedule explained

Why does the 1.0mg step exist rather than jumping straight to a higher dose?

Semaglutide works by activating GLP-1 receptors involved in appetite regulation and gastric emptying. That slowing of digestion is what curbs hunger, but it is also the reason nausea, bloating and gut discomfort are common early on. The graduated schedule (rising roughly every four weeks) gives these effects time to settle before the dose goes any higher.

At 1.0mg, most people are about two months into treatment. Some notice appetite suppression becoming more consistent; others are still primarily managing tolerability. Both experiences are normal at this stage. The full Wegovy treatment overview explains the broader arc of the five-dose journey, including what the clinical evidence shows about how weight loss accumulates as the dose rises toward maintenance.

Titration pace is always a clinical judgement. If side effects are difficult at the preceding 0.5mg step, which our dedicated guide covers in full, a prescriber may extend that step before moving to 1.0mg. Equally, if 1.0mg is well tolerated, the schedule moves forward on time. Neither version is unusual. A question our prescribers hear regularly is whether staying longer at 1.0mg means the treatment is not working, it does not; the schedule exists to protect tolerability, not to limit results.

What should you expect at the 1.0mg dose in terms of effect and side effects?

The main therapeutic effects of semaglutide (reduced appetite, smaller portions feeling satisfying, less interest in high-fat or high-sugar foods) tend to become noticeably stronger between 1.0mg and the doses that follow, as our Wegovy 1.0 guide explores. At 1.0mg you may be experiencing the beginning of that shift, or you may still be primarily in the adjustment phase. The NHS semaglutide medicines page describes the common side effects across all doses, including nausea, diarrhoea, constipation, headache and fatigue. These are most pronounced after each dose increase and typically ease within days to two weeks.

Injection-site reactions (mild redness or itching at the site) can occur at any strength. Rotating between your abdomen, thigh, and upper arm with each weekly dose reduces this. On the storage front, a small practical detail makes a difference: keeping your pen in the fridge door rather than pushed to the back keeps it at the right temperature without the freeze risk that comes from contact with the ice box.

Rare but serious reactions include signs of pancreatitis (severe stomach pain that spreads to the back, with or without vomiting) and gallbladder symptoms. These warrant urgent medical attention. The MHRA highlighted acute pancreatitis as a known serious risk for GLP-1 medicines in its January 2026 Drug Safety Update; any suspected side effect can be reported via the Yellow Card scheme.

Who is on the 1.0mg step, and does the dose itself change who qualifies for Wegovy?

Every patient on Wegovy 1.0mg was, by definition, first assessed as suitable for Wegovy overall. The licensed eligibility criteria centre on adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related condition such as high blood pressure, raised cholesterol, obstructive sleep apnoea or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

The 1.0mg strength does not unlock separate eligibility, it is simply where the schedule is at week nine to twelve of treatment. If you are considering starting Wegovy for the first time, the relevant question is whether you meet the criteria for the treatment, not whether a specific intermediate dose suits you. The num consultation page explains how our prescribers assess suitability before any treatment is issued. NICE's appraisal of semaglutide injection (NICE TA875) sets out the clinical recommendation criteria if you want to understand how NICE frames eligibility for weight management use.

For people transferring to Wegovy from another semaglutide product (including Ozempic, which is licensed for type 2 diabetes rather than weight management) the starting point in the Wegovy schedule depends on prescriber assessment, not simply matching the previous dose number. That is a conversation for your clinician, not a self-managed switch. The page on semaglutide for weight loss covers the distinction between the different branded forms.

How does 1.0mg semaglutide compare to where the weight-loss results really build?

The headline figures from the STEP 1 trial (around 15% average body-weight reduction over 68 weeks) were generated at the 2.4mg maintenance dose, not at intermediate steps. Weight loss does begin during titration, but the sustained effect the trial evidence measures is at maintenance. That context matters because some people worry when progress feels modest at 1.0mg. The dose is not designed to deliver maximum effect; it is designed to get you safely to the dose that does.

The 2024 approval of a 7.2mg maintenance dose (and, in April 2026, a dedicated single-dose 7.2mg pen) extends the ceiling further for adults with obesity. Those developments are discussed on the Wegovy 1mg guide and in the Wegovy cost and pricing overview, where the practical implications of longer titration schedules are also covered. Dose availability and which pen format is right for you is always confirmed at clinical consultation, it is not something to plan in advance of prescriber input.

If you are mid-titration and wondering whether continuing is the right call, the honest answer is: that is exactly the kind of question worth raising with your prescriber, not resolving through self-adjustment. Treatment should sit with someone who can see your full picture.